JP Morgan Chase’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.67M | Buy |
80,817
+8,062
| +11% | +$174K | ﹤0.01% | 4245 |
|
|
2025
Q4 | $1.73M | Buy |
72,755
+8,813
| +14% | +$180K | ﹤0.01% | 4191 |
|
|
2025
Q3 | $870K | Buy |
63,942
+3,280
| +5% | +$34.1K | ﹤0.01% | 4691 |
|
|
2025
Q2 | $494K | Buy |
60,662
+7,943
| +15% | +$67.8K | ﹤0.01% | 4793 |
|
|
2025
Q1 | $414K | Buy |
52,719
+9,368
| +22% | +$109K | ﹤0.01% | 4882 |
|
|
2024
Q4 | $645K | Sell |
43,351
-334
| -0.8% | -$5.46K | ﹤0.01% | 4909 |
|
|
2024
Q3 | $668K | Buy |
43,685
+1,117
| +3% | +$17.6K | ﹤0.01% | 4722 |
|
|
2024
Q2 | $648K | Buy |
42,568
+2,342
| +6% | +$37.8K | ﹤0.01% | 4537 |
|
|
2024
Q1 | $759K | Sell |
40,226
-39,662
| -50% | -$686K | ﹤0.01% | 4529 |
|
|
2023
Q4 | $1.53M | Buy |
79,888
+1,569
| +2% | +$25.1K | ﹤0.01% | 4034 |
|
|
2023
Q3 | $1.41M | Sell |
78,319
-1,481
| -2% | -$29.8K | ﹤0.01% | 3828 |
|
|
2023
Q2 | $1.62M | Sell |
79,800
-460,195
| -85% | -$8.76M | ﹤0.01% | 3697 |
|
|
2023
Q1 | $9.85M | Buy |
539,995
+25,084
| +5% | +$479K | ﹤0.01% | 2300 |
|
|
2022
Q4 | $10.6M | Buy |
514,911
+11,178
| +2% | +$308K | ﹤0.01% | 2192 |
|
|
2022
Q3 | $13.2M | Sell |
503,733
-13,459
| -3% | -$356K | ﹤0.01% | 1937 |
|
|
2022
Q2 | $13.1M | Buy |
517,192
+81,399
| +19% | +$1.99M | ﹤0.01% | 1946 |
|
|
2022
Q1 | $13.8M | Buy |
435,793
+167,381
| +62% | +$5.61M | ﹤0.01% | 2079 |
|
|
2021
Q4 | $10.9M | Sell |
268,412
-947
| -0.4% | -$36.7K | ﹤0.01% | 2376 |
|
|
2021
Q3 | $9.39M | Sell |
269,359
-4,374
| -2% | -$136K | ﹤0.01% | 2439 |
|
|
2021
Q2 | $7.52M | Sell |
273,733
-104,290
| -28% | -$2.98M | ﹤0.01% | 2682 |
|
|
2021
Q1 | $10.6M | Sell |
378,023
-119,119
| -24% | -$4.15M | ﹤0.01% | 2311 |
|
|
2020
Q4 | $12.9M | Buy |
497,142
+57,284
| +13% | +$1.39M | ﹤0.01% | 1992 |
|
|
2020
Q3 | $7.66M | Buy |
439,858
+28,809
| +7% | +$644K | ﹤0.01% | 2244 |
|
|
2020
Q2 | $10.2M | Buy |
411,049
+22,985
| +6% | +$620K | ﹤0.01% | 1883 |
|
|
2020
Q1 | $5.39M | Sell |
388,064
-80,300
| -17% | -$999K | ﹤0.01% | 2198 |
|
|
2019
Q4 | $4.73M | Sell |
468,364
-43,000
| -8% | -$362K | ﹤0.01% | 2720 |
|
|
2019
Q3 | $4.65M | Sell |
511,364
-3,898
| -0.8% | -$31.3K | ﹤0.01% | 2751 |
|
|
2019
Q2 | $3.98M | Buy |
515,262
+26,709
| +5% | +$267K | ﹤0.01% | 2825 |
|
|
2019
Q1 | $6.1M | Sell |
488,553
-4,260
| -0.9% | -$46.2K | ﹤0.01% | 2438 |
|
|
2018
Q4 | $5.31M | Buy |
492,813
+20,741
| +4% | +$242K | ﹤0.01% | 2532 |
|
|
2018
Q3 | $6.58M | Buy |
472,072
+215,534
| +84% | +$2.75M | ﹤0.01% | 2520 |
|
|
2018
Q2 | $3.14M | Buy |
256,538
+255,438
| +23,222% | +$4.01M | ﹤0.01% | 3052 |
|
|
2018
Q1 | $17K | Buy |
+1,100
| New | +$18.3K | ﹤0.01% | 5105 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
JP Morgan Chase's RCUS Position: Q1 2026 in Review
JP Morgan Chase increased its Arcus Biosciences (RCUS) stake by 11% in Q1 2026, buying an estimated $174K and bringing the position to 80,817 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #4245.
JP Morgan Chase first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $13.8M in Q1 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- JP Morgan Chase held 80,817 shares of Arcus Biosciences worth $1.67M as of Q1 2026.
- JP Morgan Chase bought 8,062 Arcus Biosciences shares in Q1 2026, an estimated $174K.
- Arcus Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4245 holding.
- JP Morgan Chase first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- JP Morgan Chase's Arcus Biosciences position peaked at $13.8M in Q1 2022.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.